文献速递心脑血管急症重症综合管理与镇静镇痛

吡仑帕奈治疗神经重症监护病房难治性癫痫持续状态

Perampanel Treatment for Refractory Status Epilepticus in a Neurological Intensive Care Unit.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论回顾性研究显示吡仑帕奈作为添加治疗可能对难治性癫痫持续状态有效,36.4%达应答,局灶运动型和惊厥型似乎优于非惊厥型。

该单中心回顾性研究纳入67例难治性癫痫持续状态(RSE)患者,其中22例接受吡仑帕奈治疗。应答定义为吡仑帕奈作为最后一种抗癫痫药物使用后4天内癫痫发作终止且住院期间无复发,8例(36.4%)达应答,另1例治疗4天后应答。应答者中局灶运动型2/2(100%)、惊厥型5/15(33.3%)、非惊厥型1/5(20%)。作者认为吡仑帕奈可能对RSE有效,且对局灶运动型和惊厥型似乎优于非惊厥型,但需进一步研究明确不同亚型的疗效。

要点

  • 22例RSE患者接受吡仑帕奈治疗,8例(36.4%)在4天内发作终止且住院期间无复发,达应答标准。
  • 吡仑帕奈作为最后一种抗癫痫药物时,9例(40.1%)患者应答,其中1例在治疗4天后才应答。
  • 应答者中局灶运动型癫痫持续状态2/2(100%)、惊厥型5/15(33.3%)、非惊厥型1/5(20%)。
  • 吡仑帕奈治疗后发作期和发作间期脑电活动减少,3例(13.6%)在末次随访时预后较好。
  • 作者认为吡仑帕奈可能对多种抗癫痫药物失败的RSE有效,且对局灶运动型和惊厥型似乎优于非惊厥型。

适用人群与场景

  • 神经重症监护病房中连续纳入的67例难治性癫痫持续状态患者,其中22例接受吡仑帕奈治疗。

诊断标准与关键阈值

  • 应答定义:吡仑帕奈作为最后一种抗癫痫药物使用后4天内癫痫发作终止,且住院期间无复发。

研究设计与关键结果

  • 研究类型:单中心回顾性研究,纳入67例RSE患者,其中22例接受吡仑帕奈治疗。
  • 主要终点:22例中8例(36.4%)达应答标准,另1例在治疗4天后应答。
  • 吡仑帕奈作为最后一种抗癫痫药物时,9例(40.1%)患者应答。
  • 应答者中局灶运动型SE 2/2(100%)、惊厥型SE 5/15(33.3%)、非惊厥型SE 1/5(20%)。
  • 吡仑帕奈治疗后发作期和发作间期脑电活动减少,3例(13.6%)在末次随访时预后较好。

证据类型、等级与局限

  • 证据类型:单中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为吡仑帕奈可能作为RSE的添加治疗,即使患者已多种抗癫痫药物失败。
  • 作者认为吡仑帕奈对局灶运动型SE和惊厥型SE可能比非惊厥型SE更有效,但既往研究多聚焦非惊厥型SE,需进一步研究明确不同亚型的疗效。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVE: Perampanel is a novel anti-epileptic drug (AED) which acts as a non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist to reduce glutamate-mediated postsynaptic excitation. Previous animal studies and a few case reports/series have suggested that it may be effective to treat refractory status epilepticus (RSE).

METHODS: We retrospectively reviewed 67 consecutive patients with RSE, of whom 22 received perampanel. The clinical features, epidemiology-based mortality score in status epilepticus, status epilepticus severity score, seizure control, functional outcome, RSE etiology, and electroencephalogram findings were collected. Responder to perampanel was defined as seizure resolution within 4 days of therapy with perampanel being the last AED used plus no recurrence during hospitalization.

RESULTS: Eight of the 22 (36.4%) RSE patients fulfilled the definition of responder to perampanel. An additional 1 patient responded to perampanel after 4 days of treatment. In total, perampanel was the last AED in 9 (40.1%) patients. Among the 8 responders to perampanel, 5 had convulsive SE, 1 had non-convulsive SE, and 2 had focal motor SE. The responders accounted for both of the patients with focal motor SE (100%), 5 (33.3%) of the 15 patients with convulsive SE, and 1 (20%) of the 5 patients with non-convulsive SE. The ictal and inter-ictal activities also decreased after perampanel therapy, and three patients (13.6%) had preferable outcomes at last follow-up.

CONCLUSIONS: Perampanel may be an effective add-on treatment for RSE even in patients who failed multiple AEDs. Our study suggests that perampanel may be more effective for focal motor SE and convulsive SE than non-convulsive SE. As most previous studies have focused on non-convulsive SE, further studies are warranted to clarify the effectiveness of perampanel for different subtypes of SE.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Ho CJ, Lin CH, Lu YT, et al. Perampanel Treatment for Refractory Status Epilepticus in a Neurological Intensive Care Unit. Neurocrit Care. 2019. PMID: 30891695. doi:10.1007/s12028-019-00704-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。